Bispecific HER2 ligands for cancer therapy
US10093740B2 · kind B2 · utility
0Cited by
0References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2013 |
| Grant date | Oct 9, 2018 |
| Priority date | — |
| Expiry date | Oct 14, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2318/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.